Trazodone Should NOT Be Used for Insomnia According to Current Guidelines
The American Academy of Sleep Medicine (AASM) explicitly recommends AGAINST using trazodone for insomnia treatment in adults. 1111 This is a formal guideline recommendation, not merely a lack of endorsement.
The Guideline Position
The 2017 AASM Clinical Practice Guideline states: "We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults." This recommendation is based on trials using 50 mg doses of trazodone and reflects that harms outweigh benefits (moderate quality evidence). 1111
The American College of Physicians (2016) similarly found insufficient evidence to support trazodone use for insomnia, noting that "commonly used older and generic medications, such as diphenhydramine and trazodone, have not been studied" adequately. 2
Why This Matters Despite Common Practice
While trazodone is widely prescribed off-label for insomnia in clinical practice, the evidence base does not support this use when prioritizing patient safety and outcomes:
- No FDA approval for insomnia treatment 3
- Insufficient high-quality evidence for efficacy
- Documented harms including priapism (reported in 12% in one PTSD study—far higher than expected) 4, hypotension, dizziness, and sedation 56
- Better alternatives exist with proven efficacy (see below)
If Trazodone Is Used Despite Guidelines (Doses from Available Studies)
If clinicians choose to use trazodone off-label despite guideline recommendations, the literature reports:
- 25-100 mg nightly for insomnia in various populations 57
- 50-75 mg for hypnotic effects in depression-related insomnia 8
- 50-100 mg (with 100 mg showing better efficacy) in depressive states 9
- 50-200 mg range effective in 70% of PTSD patients 4
The FDA label does not provide insomnia dosing as this is not an approved indication. 3
Recommended Alternatives with Guideline Support
Instead of trazodone, the AASM recommends:
- Cognitive Behavioral Therapy for Insomnia (CBT-I) as first-line treatment 2
- For sleep onset insomnia: Zolpidem 10 mg, zaleplon 10 mg, triazolam 0.25 mg, ramelteon 8 mg 11
- For sleep maintenance insomnia: Suvorexant (10-20 mg), eszopiclone (2-3 mg), doxepin (3-6 mg), zolpidem 10 mg 11
Critical Caveats
- Priapism risk: Directly ask male patients about this potentially serious adverse effect 4
- Cardiovascular effects: Monitor for hypotension, particularly in elderly patients 5
- Drug interactions: Exercise caution with concurrent psychotropics, though some data suggest safety with MAOIs at low doses 8
- Lack of long-term data: Most studies are short-term; chronic use lacks safety evidence
The evidence-based approach prioritizes FDA-approved agents with demonstrated efficacy and safety profiles over trazodone for primary insomnia treatment.